drugset / Trial / NCT04966546

Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)

NCT04966546

Phase 0 Withdrawn University of New Mexico
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Chronic Subdural Hematoma (cSDH) is an extremely common problem, particularly in the aging population, where fluid like collections compress the brain, frequently requiring surgical drainage. After drainage, 25-50% of patients experience post operative neurologic deficits such as weakness or confusion that are often not explained by problems such as seizure, stroke, or mass effect from the fluid and blood. Recent subdural recordings have demonstrated that some of these neurological deficits may be related to waves of spreading depolarization (SD), which cause temporary neurological dysfunction. Our overall objective is to examine the relationship between neurological deficits and SD and to assess feasibility of a pilot trial to determine if a strategy of NMDA-R antagonism can effectively reduce SD and improve clinical recovery.

Timeline

Start
2022-06-01
Primary completion
2025-12-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg Oral

Indications

No indication recorded.